文献速递肥胖与代谢综合征

患者管理方法:肠促胰岛素激动剂停药后的临床结局与过渡策略

Approach to the Patient: Clinical Outcomes and Interim Strategies Following Discontinuation of Incretin Agonists.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

本文综述肥胖药物治疗(OMs)可带来约5%-24%的体重下降并改善心脏代谢健康,但多达半数患者在1至2年内因副作用、可及性、费用或反应不足而停药。停药常导致体重反弹和健康获益逆转,文章通过2例真实世界病例展示停药后反应减弱或体重反弹的情况,并概述减轻体重反弹、长期维持健康改善的实用方法。

要点

  • 肥胖药物停药后常出现体重反弹及健康获益逆转。
  • 多达半数患者在1至2年内停药,原因包括副作用、费用和可及性。
  • 需识别有效过渡策略以维持体重管理进展。

核心结论

  • 停用肥胖药物常导致体重反弹和相关健康获益逆转,需制定过渡策略以维持长期体重管理。

研究设计与样本

  • 本文为J Clin Endocrinol Metab发表的「患者管理方法」文章,通过2例真实世界病例展示肥胖药物治疗中断后的临床结局。

主要发现

  • 肥胖药物可产生约5%-24%的体重下降并改善心脏代谢健康。
  • 多达半数患者在1至2年内因副作用、可及性有限、费用或反应不足而停药。
  • 2例患者分别出现对重新开始治疗反应减弱和/或体重反弹。

临床怎么用

  • 临床应关注肥胖药物停药后的体重反弹风险,并采用实用方法减轻反弹、维持长期健康改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The global rise in obesity has led to an increasing need for pharmacologic therapies as adjuncts to lifestyle interventions for weight management. While obesity medications (OMs) produce meaningful weight loss (∼5%-24%) and improve cardiometabolic health, up to half of patients discontinue treatment within 1 to 2 years due to side effects, limited access, cost, or inadequate response. Discontinuation of OMs, however, often results in weight regain and reversal of associated health benefits, posing considerable clinical challenges. Understanding the outcomes following cessation of pharmacotherapy and identifying effective interim strategies are essential to maintaining progress in weight management and minimizing long-term health risks. This approach to the patient article demonstrates 2 cases of patients in the real-world setting who experience disruption of their obesity regimen with either a blunted response to reintroduction of therapy and/or weight regain and outlines practical approaches to mitigate weight regain and sustain health improvements long term in patients with obesity.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Barenbaum SR, Aras M, Kashyap S, et al. Approach to the Patient: Clinical Outcomes and Interim Strategies Following Discontinuation of Incretin Agonists. J Clin Endocrinol Metab. 2026. PMID: 41314250. doi:10.1210/clinem/dgaf641

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。